Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics
GET POWR RATINGS... FREE!
VBLT Stock Summary
- VBLT has a higher market value than only 3.41% of US stocks; more precisely, its current market capitalization is $10,671,768.
- With a year-over-year growth in debt of -69.44%, VASCULAR BIOGENICS LTD's debt growth rate surpasses just 3.25% of about US stocks.
- The volatility of VASCULAR BIOGENICS LTD's share price is greater than that of 98.27% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to VASCULAR BIOGENICS LTD are ATNM, BLDP, IMGN, TMBR, and VSTM.
- VBLT's SEC filings can be seen here. And to visit VASCULAR BIOGENICS LTD's official web site, go to www.vblrx.com.
VBLT Valuation Summary
- In comparison to the median Healthcare stock, VBLT's EV/EBIT ratio is 97.67% lower, now standing at 0.2.
- Over the past 99 months, VBLT's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for VBLT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VBLT | 2022-11-25 | 12.1 | 0.4 | -0.3 | 0.2 |
| VBLT | 2022-11-23 | 12.4 | 0.4 | -0.3 | 0.2 |
| VBLT | 2022-11-22 | 11.4 | 0.4 | -0.3 | 0.2 |
| VBLT | 2022-11-21 | 10.9 | 0.4 | -0.2 | 0.2 |
| VBLT | 2022-11-18 | 10.7 | 0.4 | -0.2 | 0.2 |
| VBLT | 2022-11-17 | 10.8 | 0.4 | -0.2 | 0.2 |
VBLT Growth Metrics
- Its 4 year price growth rate is now at -78.76%.
- The 3 year net cashflow from operations growth rate now stands at -82.46%.
- Its 2 year net income to common stockholders growth rate is now at -64.75%.
The table below shows VBLT's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 0.854 | -31.508 | -38.139 |
| 2022-06-30 | 0.572 | -31.563 | -35.471 |
| 2022-03-31 | 0.696 | -27.27 | -34.065 |
| 2021-12-31 | 0.768 | -24.984 | -29.92 |
| 2021-09-30 | 0.777 | -25.545 | -28.07 |
| 2021-06-30 | 0.771 | -22.289 | -27.345 |
VBLT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VBLT has a Quality Grade of C, ranking ahead of 42.6% of graded US stocks.
- VBLT's asset turnover comes in at 0.015 -- ranking 380th of 682 Pharmaceutical Products stocks.
- ISEE, SRNE, and CNCE are the stocks whose asset turnover ratios are most correlated with VBLT.
The table below shows VBLT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.015 | 0.403 | -1.059 |
| 2021-03-31 | 0.016 | 0.418 | -0.951 |
| 2020-12-31 | 0.020 | 0.573 | -0.863 |
| 2020-09-30 | 0.018 | 0.724 | -0.741 |
| 2020-06-30 | 0.015 | 0.742 | -0.740 |
| 2020-03-31 | 0.014 | 0.749 | -0.628 |
VBLT Price Target
For more insight on analysts targets of VBLT, see our VBLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $5.38 | Average Broker Recommendation | 1.38 (Strong Buy) |
VBLT Stock Price Chart Interactive Chart >
VBLT Price/Volume Stats
| Current price | $0.15 | 52-week high | $2.29 |
| Prev. close | $0.15 | 52-week low | $0.11 |
| Day low | $0.15 | Volume | 1,557,900 |
| Day high | $0.16 | Avg. volume | 1,452,327 |
| 50-day MA | $0.14 | Dividend yield | N/A |
| 200-day MA | $0.90 | Market Cap | 10.61M |
Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio
Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.
Latest VBLT News From Around the Web
Below are the latest news stories about VASCULAR BIOGENICS LTD that investors may wish to consider to help them evaluate VBLT as an investment opportunity.
H.C. Wainwright Reaffirms Their Hold Rating on Vascular Biogenics (VBLT)In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Hold rating on Vascular Biogenics (VBLT - Research Report). The company's shares closed yesterday at $0.13.According to TipRanks, Ramakanth is an analyst with an average return of -16.4% and a 27.74% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, Innate Pharma, and EDAP TMS.The word on The Street in general, suggests a Hold analyst consensus rating for Vascular Biogenics.See today’s best-performing stocks on TipRanks >>The company has a one-year high of $2.38 and a one-year low of $0.11. Currently, Vascular Biogenics has an average volume of 1.59M. |
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue EstimatesVascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateContinued progress on previously announced strategic process to maximize shareholder valueTEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update. “VBL’s management team and board continue to make good progress on the evaluation of strategic |
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue EstimatesOYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine. |
VBLT Price Returns
| 1-mo | 20.00% |
| 3-mo | N/A |
| 6-mo | -90.20% |
| 1-year | -92.99% |
| 3-year | -88.00% |
| 5-year | -97.66% |
| YTD | -92.39% |
| 2021 | 4.23% |
| 2020 | 57.50% |
| 2019 | 23.71% |
| 2018 | -86.34% |
| 2017 | 46.39% |
Continue Researching VBLT
Want to do more research on Vascular Biogenics Ltd's stock and its price? Try the links below:Vascular Biogenics Ltd (VBLT) Stock Price | Nasdaq
Vascular Biogenics Ltd (VBLT) Stock Quote, History and News - Yahoo Finance
Vascular Biogenics Ltd (VBLT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...